Form 4: T2 Biosystems Director John Cumming Receives 35,000 Restricted Stock Units

Director John Cumming of T2 Biosystems was granted 35,000 restricted stock units that vest in two equal annual installments.

Summary

• John Cumming, a director at T2 Biosystems, received 35,000 restricted stock units (RSUs) on November 4, 2024.
• These RSUs will vest in two equal annual installments, starting on November 4, 2025.
• The grant was contingent on stockholder approval of the amendment and restatement of the company's 2014 Incentive Award Plan.
• Stockholders approved the plan amendment on December 30, 2024.
• Each RSU represents a right to receive one share of T2 Biosystems common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock-based compensation, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

The granting of stock-based compensation is a common practice for public companies to incentivize and retain key personnel, such as directors.

Comparison to Industry Standards

• Stock-based compensation is a standard practice across the biotechnology industry, with companies like Exact Sciences (EXAS) and Bio-Rad Laboratories (BIO) also using RSUs as part of their compensation packages.
• The vesting schedule of two years is also typical, aligning with industry norms for long-term incentives.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns the director's interests with the company's long-term performance.
• The grant does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Restricted Stock Units, RSU, Stock Grant, Incentive Award Plan, Director Compensation, T2 Biosystems, TTOO